Ironwood Pharmaceuticals
IRWD
Market cap $135M

0.8331 USD

-0.0569

6.39%

At close Jul 30, 4:00 PM EDT

After hours

0.8265

-0.0066

0.79%

1 day

-6.39%

5 days

-4.55%

1 month

16.16%

3 months

-10.64%

6 months

-63.78%

Year to date

-80.76%

1 year

-88.00%

5 years

-91.16%

10 years

-90.50%

About: Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Employees: 253

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

164,720% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $10K

16% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 63

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

5.39% less ownership

Funds ownership: 102.61% [Q4 2024] → 97.23% (-5.39%) [Q1 2025]

10% less funds holding

Funds holding: 223 [Q4 2024] → 201 (-22) [Q1 2025]

39% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 51

69% less capital invested

Capital invested by funds: $727M [Q4 2024] → $229M (-$499M) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for IRWD.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

Zacks Investment Research

IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates

Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.

IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates

Zacks Investment Research

Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.

Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st.

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Zacks Investment Research

Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood.

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced it reiterates its full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and raises its adjusted EBITDA guidance. Ironwood plans to report full first quarter 2025 results in early May. “Today, we are reiterating our full-year 2025 LINZESS U.S. net s.

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present real-world data during the 2025 Digestive Disease Week® (DDW) meeting, taking place May 3-6 in San Diego, CA. These data will focus on the adoption and utilization of recently approved ICD-10 (International Statistical Classification of Di.

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Zacks Investment Research

Ironwood Shares Tank on Regulatory Update for Apraglutide

Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.

Ironwood Shares Tank on Regulatory Update for Apraglutide

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

See News Rankings

Charts implemented using Lightweight Charts™